Proteome Sciences shares rise as chair hails rebound in business

(Alliance News) - Proteome Sciences PLC on Friday said demand for its proteomics business has "rebounded strongly" and it is optimistic for the future.

Shares in Proteome Sciences were up 21% to 3.94 pence in London on Friday afternoon.

The London-based protein-focused drug development services provider said it is optimistic that its proteomics business is well positioned for "substantial future increases in revenue and returns".

It said its pipeline of orders continues to expand and has extended "well into 2026".

Chair Christopher Pearce said at the company's annual general meeting that there was a similar trend in expanding orders at its San Diego facility.

On tariffs, Pearce commented: "It is too early to establish whether the recent tariff changes by the US government could affect [tandem mass tag] reagent revenues, but any impact is likely to be short-lived."

The chair added that licensing discussions for its new DXT tags for multiplexing in data-independent acquisition mass spectometry have continued to progress positively.

"After completing our first commercial single cell proteomics project in January, we are discussing a follow up order with the same customer with other SCP projects ongoing. The extra capacity from the two additional mass spectrometry systems installed at our main Frankfurt site are working at full capacity to meet the increased level of orders in our services business," Chair Pearce added.

By Michael Hennessey, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Proteome